ICOTF - iCo Therapeutics Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0480
0.0000 (0.00%)
At close: 11:18AM EDT
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close0.0480
Open0.0480
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0480 - 0.0480
52 Week Range0.0220 - 0.2040
Volume1,000
Avg. Volume4,028
Market Cap6.561M
Beta (3Y Monthly)3.16
PE Ratio (TTM)N/A
EPS (TTM)-0.0150
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile26 days ago

    iCo Therapeutics Announces 2018 Year End Financial Results

    Vancouver, British Columbia--(Newsfile Corp. - April 30, 2019) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today reported financial results for the year ended December 31, 2018. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").Stated Andrew Rae, President and CEO of iCo Therapeutics Inc., "2018 represented a year of significant advances as we entered into a clinical trial for Oral Amphotericin B ...

  • Newsfile3 months ago

    iCo Therapeutics Inc. Announces the Issuance of 3,600,000 Units Pursuant to its Non-Brokered Private Placement

    Vancouver, British Columbia--(Newsfile Corp. - March 5, 2019) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") is pleased to announce that it has issued a further 3,600,000 units ("Units") pursuant to its previously announced non-brokered private placement (the "Private Placement"). The Units were sold at a price of $0.05 per Unit, for total gross proceeds to the Company of C$180,000 (the "Fourth Tranche"), bringing the total number of Units ...

  • Newsfile3 months ago

    iCo Therapeutics Inc. Announces the Issuance of 14,400,000 Units Pursuant to its C$1,250,000 Non-Brokered Private Placement

    Vancouver, British Columbia--(Newsfile Corp. - February 25, 2019) -  iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") is pleased to announce that it has issued a total of 14,400,000 units (the "Units") pursuant to its previously announced non-brokered private placement (the "Private Placement"). The Units were sold at a price of $0.05 per Unit, for total gross proceeds to the Company of C$720,000.Each Unit issued pursuant to the Private Placement consists ...

  • Newsfile3 months ago

    iCo Therapeutics Inc. Announces Upsizing of Non-Brokered Private Placement to $1,250,000 CDN

    Vancouver, British Columbia--(Newsfile Corp. - February 19, 2019) -  iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") announces an upsizing of a previously announced Non-brokered private placement to $1,250,000 CDN.Each Unit issued pursuant to the Private Placement consists of one common share in the capital of the Company (a "Common Share") and one common share purchase warrant (a "Warrant") exercisable at $0.075 for 36 months from the date of the closing ...

  • Newsfile3 months ago

    iCo Therapeutics Inc. Announces Notice of Termination of Sub License for Bertilimumab (iCo-008)

    Vancouver, British Columbia--(Newsfile Corp. - February 19, 2019) -  iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") announces that on Friday February 15, 2019 the Company delivered written notice terminating, with immediate effect, its product sublicense agreement with Immune Pharmaceuticals (IMNP: OTCQB), related to iCo-008 (Bertilimumab). Subsequent to the above noted termination, Immune Pharmaceuticals filed a voluntary petition for bankruptcy in the District of New Jersey on February 17, 2019.https://www.pacermonitor.com/public/case/27133041/Immune_Pharmaceuticals_IncAbout ...

  • Newsfile3 months ago

    iCo Therapeutics Inc. Announces the Issuance of 4,000,000 Units Pursuant to its C$750,000 Non-Brokered Private Placement

    Vancouver, British Columbia--(Newsfile Corp. - February 11, 2019) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") is pleased to announce that it has issued a total of 4,000,000 units (the "Units") to a Canadian institutional investor pursuant to its previously announced non-brokered private placement (the "Private Placement"). The Units were sold at a price of $0.05 per Unit, for total gross proceeds to the Company of C$200,000. ...

  • Newsfile4 months ago

    iCo Therapeutics Inc. Announces Non-Brokered Private Placement to Raise C$750,000

    Vancouver, British Columbia--(Newsfile Corp. - January 31, 2019) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQX: ICOTF) ("iCo" or "the Company") is pleased to announce that it has issued a total of 3,000,000 units (the "Units") pursuant to the first tranche of a non-brokered private placement (the "Private Placement"). The Company plans to issue up to 15,000,000 Units at a price of $0.05 per Unit for total gross proceeds of $750,000 pursuant to ...

  • Newsfile6 months ago

    iCo Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Update

    Vancouver, British Columbia--(Newsfile Corp. - November 29, 2018) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today reported financial results for the quarter and nine months ended September 30, 2018. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").Stated Andrew Rae, President and CEO of iCo Therapeutics Inc., "This quarter was a period of significant achievement for iCo Therapeutics and its wholly-owned subsidiary, ...

  • Newsfile6 months ago

    iCo Therapeutics Provides Corporate Update, Including Drug Supply for Next Oral Amphotericin B Efficacy Study

    Vancouver, British Columbia--(Newsfile Corp. - November 15, 2018) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today announced several positive corporate developments and updated guidance on milestones for two drug candidates.-iCo Therapeutics announces that it now has sufficient drug supply for a proposed mid-staged clinical trial, which may be as large as 90 patients in size, investigating the efficacy and safety study of its oral Amphotericin B (oral Amp B) ...

  • Newsfile7 months ago

    iCo Therapeutics Announces Oral Amphotericin B Clinical Advisory Board

    Vancouver, British Columbia--(Newsfile Corp. - October 23, 2018) -  iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today announced the formation of an oral Amphotericin B clinical advisory board with the appointment of Dr. John Perfect and Dr. David Denning.Stated Dr. Peter Hnik, Chief Medical Officer, "we look forward to working with our clinical advisors as we refine the design of mid staged clinical studies for our oral Amphotericin B candidate. We ...

  • Newsfile8 months ago

    iCo Therapeutics Provides Corporate Update

    Vancouver, British Columbia--(Newsfile Corp. - October 2, 2018) -  iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today announced several positive corporate developments and updated guidance on milestones for two drug candidates.iCo Therapeutics Australia Pty Ltd. has received full payment of approximately $462,000 Australian dollars (AUD) for R&D expenditures conducted during its past fiscal year, during which the Company conducted a Phase 1 clinical study. Refundable cash tax credits at a reimbursement rate for ...

  • Newsfile9 months ago

    iCo Therapeutics Announces Additional Positive Pharmacokinetic Results and Presentation at Global Investment Conference

    Vancouver, British Columbia--(Newsfile Corp. - September 6, 2018) - iCo Therapeutics ("iCo" or the "Company") (TSXV: ICO) (OTCQB: ICOTF), today announced additional positive pharmacokinetic data from its recent Phase 1 study of its Oral Amphotericin B (Oral Amp B) candidate. Previously the Company reported that Oral Amp B achieved a median Cmax of 28 ng/mL and AUC0-inf of 1030 hr*ng/mL at the lowest dose of Oral Amphotericin B of 100 mg, demonstrating superiority of ...

  • Associated Press9 months ago

    Ico Therapeutics: 2Q Earnings Snapshot

    The Vancouver, British Columbia-based company said it had a loss of 1 cent per share. In the final minutes of trading on Wednesday, the company's shares hit 8 cents. A year ago, they were trading at 4 ...

  • Newsfile9 months ago

    iCo Therapeutics Announces Second Quarter 2018 Financial Results And Corporate Update

    Vancouver, British Columbia--(Newsfile Corp. - August 29, 2018) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today reported financial results for the quarter and six months ended June 30, 2018. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").Stated Andrew Rae, President and CEO of iCo Therapeutics Inc., "the quarter represented a period of significant achievement for iCo Therapeutics with respect to its two clinical ...

  • Newsfile10 months ago

    iCo Therapeutics Announces Positive Secondary Endpoint and Advancement into Later Stage Clinical Trials - Phase 1 Oral Amphotericin B

    Vancouver, British Columbia--(Newsfile Corp. - July 16, 2018) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), and its subsidiary iCo Therapeutics Australia Pty Ltd., today announced a positive pharmacokinetic secondary end point in its Phase 1 clinical study. Previously the Company reported that the study met its primary endpoint of safety and tolerability of iCo-019 (Oral Amp B) following oral administration of single ascending doses (4 dose levels) in healthy subjects, including ...

  • Newsfile11 months ago

    iCo Therapeutics Announces Positive Clinical Outcome - Primary Endpoint Met in Phase 1 Oral Amphotericin B Study

    Vancouver, British Columbia--(Newsfile Corp. - June 27, 2018) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), and its subsidiary iCo Therapeutics Australia Pty Ltd., today announced a positive primary end point in its Phase 1 clinical study. The study met its primary endpoint of safety and tolerability of iCo-019 (Oral Amp B) following oral administration of single ascending doses (4 dose levels) in healthy subjects. There were no serious adverse ...

  • Newsfile11 months ago

    iCo Therapeutics Provides Corporate Update, Announces Completion of Phase 1 Recruitment

    Vancouver, British Columbia--(Newsfile Corp. - June 20, 2018) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today announced the completion of recruitment of all 32 subjects in the Company's Phase 1 Oral Amphotericin B (Oral Amp B) study. Phase 1 Oral Amp B Clinical TrialThe Phase 1 Australian study is a randomized, double-masked, placebo-controlled, single dose ascending study to assess the safety, tolerability, and bioavailability of iCo-019 (Oral Amphotericin B). Subjects ...

  • Newsfilelast year

    iCo Therapeutics Announces First Quarter 2018 Financial Results And Update On Phase 1 Clinical Trial

    Vancouver, British Columbia--(Newsfile Corp. - May 30, 2018) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today reported financial results for the quarter ended March 31, 2018. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS")."Recently, we dosed our first subject with our novel Oral Amphotericin B (Oral AmpB) formulation. Strong recruitment has resulted in our dosing of all subjects in three of ...